Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783770 | 0.95 | TERT (0.38) | PDE5ATERTRXFP1CNR2MAPK1 | |
| SCHEMBL12317587 | 0.82 | PDE5A (0.36) | PDE5ATERTRXFP1CNR2MAPK1 | |
| SCHEMBL6779389 | 0.79 | PDE5A (0.43) | PDE5ATERTRXFP1KIT | |
| SCHEMBL6196402 | 0.76 | HDAC8 (0.51) | PDE5ATERT | |
| SCHEMBL6363377 | 0.74 | PDE5A (0.42) | PDE5ARXFP1 | |
| SCHEMBL6895181 | 0.73 | TERT (0.60) | PDE5ATERT | |
| SCHEMBL2402678 | 0.73 | PDE5A (0.53) | PDE5ACNR2 | |
| SCHEMBL6746112 | 0.72 | PDE5A (0.42) | PDE5ATERTCNR2 | |
| SCHEMBL6356946 | 0.72 | PDE5A (0.52) | PDE5ACNR2 | |
| SCHEMBL6356420 | 0.72 | PDE5A (0.38) | PDE5ARXFP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | disclosed |
| EP-1440709-B1 | Combinations comprising cGMP PDE5 inhibitors. | PFIZER LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| EP-1149579-B1 | Use of an estrogen agonist/antagonist for treating female sexual dysfunction | PFIZER PROD INC (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20050143367-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | PFIZER INC | 2005-06-30 | — | — | US | disclosed |
| US-6809200-B2 | REACTING 5-ACETYL-N-(3-(AMINOCARBONYL)-5-ETHYL-1-(1-ETHYL-3-AZETIDINYL)-1H-PYRAZOL4 -YL)-2-ETHOXYNICOTINAMIDE, IN PRESENCE OF ALCOHOL OR ALKOXY COMPOUND AND A HYDROXIDE TRAPPING AGENT OR BASE | PFIZER INC. | 2004-10-26 | — | — | US | disclosed |
| EP-1440709-A2 | Combinations comprising cGMP PDE5 inhibitors. | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | disclosed |
| US-6756373-B1 | SUCH AS 5-(2-BUTOXY-5-IODO-3-PYRIDINYL)-3-ETHYL-2-(2-METHOXY-ETHYL)-2,6-DIHYDRO-7H -PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; ERECTILE DYSFUNCTION | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040122010-A1 | Treatment of neuropathy | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
| US-6699991-B2 | A ?ONE-POT? PROCESS IS DESCRIBED HEREIN FOR THE PRODUCTION OF PYRAZOLE COMPOUNDS OF GENERAL FORMULA (II) COMPRISING THE STEPS OF REACTING A COMPOUND OF GENERAL FORMULA (III) WITH AN ACYLATING AGENT IN THE PRESENCE OF A BASE AND AN OPTIONAL | PFIZER INC. | 2004-03-02 | — | — | US | disclosed |
| US-20020111498-A1 | Novel process for the preparation of pyrazoles | JAMES HARRIS LAURENCE (GB) | 2002-08-15 | — | — | US | disclosed |
| US-6407259-B1 | REACTING DIETHER COMPOUND WITH ACYLATING AGENT COMPRISING ACID ANHYDRIDE OR ACID HALIDE DERIVATIVE TO FORM PYRAZOLE DERIVATIVE | PFIZER INC. | 2002-06-18 | — | — | US | disclosed |
| US-20020038024-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | PFIZER INC. | 2002-03-28 | — | — | US | disclosed |
| US-20020022732-A1 | Novel process for the preparation of pyrazoles | PFIZER INC. | 2002-02-21 | — | — | US | disclosed |
| EP-1176147-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | Pfizer Limited (GB) | 2002-01-30 | — | — | EP | disclosed |
| EP-1176142-A1 | Process for the preparation of pyrazoles | PFIZER INC. (US) | 2002-01-30 | — | — | EP | disclosed |
| US-20010044434-A1 | Compositions and methods of treatment for conditions responsive to testosterone elevation | LEE ANDREW G (US) | 2001-11-22 | — | — | US | disclosed |
| EP-1149579-A2 | Use of an estrogen agonist/antagonist for treating female sexual dysfunction | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1129706-A2 | Use of cGMP PDE5 inhibitors for the treatment of neuropathy | Pfizer Limited (GB) | 2001-09-05 | — | — | EP | disclosed |
| EP-1125582-A2 | Use of estrogen agonists / antagonists for the treatment of sexual dysfunction | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038024-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | DPYD, HPRT1, SAMHD1 | PDE5A 1809/4885TERT 385/4885RXFP1 2604/4885 |
| US-20050143367-A1 | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof | NOX4, VKORC1, DPYD | PDE5A 1588/4885TERT 685/4885RXFP1 2585/4885 |
| US-20040122010-A1 | Treatment of neuropathy | PDE5A, PDE3A, PDE2A | PDE5A 1/4885TERT 3344/4885RXFP1 2991/4885 |
| US-20020022732-A1 | Novel process for the preparation of pyrazoles | NAT1, CYP2F1, CYP51A1 | PDE5A 1067/4885TERT 3231/4885RXFP1 4182/4885 |
| US-20010044434-A1 | Compositions and methods of treatment for conditions responsive to testosterone elevation | PDE3B, PDE3A, SHBG | PDE5A 4/4885TERT 1012/4885RXFP1 388/4885 |
| US-20020111498-A1 | Novel process for the preparation of pyrazoles | NAT1, CYP2F1, CYP51A1 | PDE5A 1067/4885TERT 3231/4885RXFP1 4182/4885 |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | PDE5A 4/4885TERT 3324/4885RXFP1 441/4885 |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | PDE5A 4/4885TERT 3324/4885RXFP1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.